NFL’s top doctor defends Philadelphia Eagles handling of Jalen Hurts blood clots but NFLPA has different story
Photo by Joshua Hoehne on Unsplash
The NFL’s top medical officer, Dr. Allen Sills, has publicly defended the Philadelphia Eagles’ handling of quarterback Jalen Hurts’ blood‑clot diagnosis. In a statement released at the league’s fall meeting, Sills emphasized that the Eagles’ medical staff acted “very conservative, very patient‑focused and appropriately guarded at every step.” He noted that the league reviews each deep‑vein thrombosis case and that the decision to keep Hurts out of the game was made “out of an abundance of caution.” Sills added that the team’s diagnostics—state‑of‑the‑art imaging performed in London—were swift and thorough, and that the NFL’s review committee works with the Players Association to learn from such incidents.
NFL vice‑president Jeff Miller also confirmed that the league had consulted with the Eagles’ staff, independent hospital doctors, and other on‑ground personnel to “have a complete understanding of the course of events.” These comments paint a picture of a league that believes it has fully vetted Hurts’ medical care.
However, the NFLPA issued a contrasting statement later that evening. The union said it was not aware of any NFL investigation into the medical care Hurts received and that the league had told the union it would not review the care. The NFLPA’s remarks suggest a disconnect between the league’s public defense and its internal handling of the situation.
The differing narratives raise questions about transparency and oversight. While the NFL’s officials maintain confidence in the Eagles’ medical approach, the union’s assertion that no review was conducted highlights a potential gap in the league’s accountability processes. The outcome of any further inquiry remains unclear, but the episode underscores the need for clear communication between the NFL, its medical staff, and the Players Association.
